Beranda › Kanker Paru › Michigan › Waterford
Uji klinis Kanker Paru di Waterford, MI
9 studi untuk Kanker Paru mencari peserta di lokasi sekitar Waterford (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Menerima pesertaFase 3
- Michigan Healthcare Professionals Pontiac, Pontiac · 7 mi jauhnya
- Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac · 7 mi jauhnya
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Hematology Oncology Consultants-Clarkston, Clarkston · 3 mi jauhnya
- Michigan Healthcare Professionals Pontiac, Pontiac · 7 mi jauhnya
- Newland Medical Associates-Pontiac, Pontiac · 7 mi jauhnya
- dan 1 lainnya
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Menerima pesertaFase 3
- Hematology Oncology Consultants-Clarkston, Clarkston · 3 mi jauhnya
- Michigan Healthcare Professionals Pontiac, Pontiac · 7 mi jauhnya
- Newland Medical Associates-Pontiac, Pontiac · 7 mi jauhnya
- dan 1 lainnya
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Hematology Oncology Consultants-Clarkston, Clarkston · 3 mi jauhnya
- Trinity Health IHA Medical Group - Primary Care - Clarkston, Clarkston · 3 mi jauhnya
- Michigan Healthcare Professionals Pontiac, Pontiac · 7 mi jauhnya
- dan 2 lainnya
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac · 7 mi jauhnya
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Menerima pesertaFase 3
- McLaren Cancer Institute-Clarkston, Clarkston · 3 mi jauhnya
- Michigan Healthcare Professionals Clarkston, Clarkston · 3 mi jauhnya
- Michigan Healthcare Professionals Pontiac, Pontiac · 7 mi jauhnya
- dan 1 lainnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac · 7 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac · 7 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Trinity Health Saint Joseph Mercy Oakland Hospital, Pontiac · 7 mi jauhnya
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Waterford
- Kanker Payudara8 studi
- Kanker Paru Non-Sel Kecil8 studi
- Leukemia Mieloid Akut7 studi
- Kanker Prostat7 studi
- Kanker Kolorektal5 studi
- Karsinoma Sel Skuamosa Kepala dan Leher4 studi
- Kanker Hipofaring4 studi
- Kanker Laring4 studi
- Kanker Mulut4 studi
- Mieloma Multipel3 studi
- Kanker (semua jenis)3 studi
- Kanker Kolon3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.